CRESCENT BIOPHARMA, INC. — Form SCHEDULE 13D/A
Filed July 20, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
Fairmount Funds Management LLC filed an amended Schedule 13D/A regarding beneficial ownership in Crescent BioPharna, Inc. (public market value ~$177.2M). The filing date is July 20, 2026. The document provided contains only header/metadata information; specific ownership percentages, share counts, dollar amounts, or changes in beneficial ownership position are not disclosed in the text excerpt provided.
Why this rating
Amendment filing alone is routine; substance of ownership change not visible in excerpt. Insufficient data to assess materiality relative to company size.
See more from July 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.